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PRELIMINARY RESEARCH Open Access
99mTc-HYNIC-IL-2 scintigraphy to detect
acute rejection in lung transplantation
patients: a proof-of-concept study
Eef D. Telenga1, Wim van der Bij2, Erik F. J. de Vries1, Erik A. M. Verschuuren2, Wim Timens3, Gert Luurtsema1,
Riemer H. J. A. Slart1,4, Alberto Signore1,5 and Andor W. J. M. Glaudemans1*
Abstract
Rationale: Acute allograft rejection is one of the major complications after lung transplantation, and adequate and
early recognition is important. Till now, the reference standard to detect acute rejection is the histopathological
grading of transbronchial biopsies (TBBs). Acute rejection is characterised by high levels of activated T lymphocytes.
Interleukin-2 (IL-2) binds specifically to high-affinity IL-2 receptors expressed on the cell membrane of activated T
lymphocytes. The aim of this proof-of-concept study was to evaluate if non-invasive imaging with 99mTc-HYNIC-IL-2
is able to detect acute rejection after lung transplantation.
Methods: 99mTc-HYNIC-IL-2 scintigraphy (static, SPECT/CT of the lungs) was performed shortly before routine
transbronchial biopsy (pathology as reference standard). Scans were scored as likely or unlikely for rejection, and
semiquantitative analysis (target-to-background ratio) was performed.
Results: Thirteen patients were included of which 3 showed acute rejection at transbronchial biopsy; in 2 of these
patients (scored as graded 2–3 at pathology), the scan was scored likely for rejection, and in 1 patient (scored
grade 1 at pathology), the scan was scored unlikely. No correlation was found between biopsy results and
semiquantitative analysis.
Conclusion: 99mTc-HYNIC-IL-2 scintigraphy proved to be a good technique to detect grade 2 and 3 acute rejection
in a small sample population of patients after lung transplantation. Larger studies are necessary to really show the
added value of this non-invasive specific imaging technique over transbronchial biopsy. Alternatively, imaging with
the PET tracer 18F-IL-2 may be useful for this purpose.
Keywords: 99mTc-HYNIC-IL-2 scintigraphy, Lung transplantation, Rejection, SPECT/CT, Imaging
Background
Lung transplantation is a therapeutic option in pa-
tients with end-stage pulmonary disease. Acute
allograft rejection is one of the major complications
after transplantation, and adequate and early recogni-
tion is of invaluable importance. However, diagnosing
and monitoring acute rejection can be difficult.
Clinical signs are non-specific and are not able to dif-
ferentiate between rejection and other causes of graft
dysfunction. Acute rejection may initially even be
clinically silent [1]. High-resolution computed tomog-
raphy (HR-CT) has an accuracy of only 53% (with
sensitivity 35% and specificity 73%) for the diagnosis
of acute rejection, and no individual HR-CT finding is
significantly correlated with this diagnosis [2]. Other
biomarkers such as C-reactive protein (CRP) and
erythrocyte sedation rate (ESR) are insensitive and
non-specific. More recently, the measurement of sev-
eral cytokines in bronchoalveolar lavage samples has
been proposed [3]. The reference standard to detect
acute rejection is still the histopathological grading of
transbronchial biopsies (TBBs). To date, in absence of
a more specific non-invasive tool for the diagnosis of
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acute rejection, many centres perform surveillance
TBB at fixed intervals during the first postoperative
year, in addition to TBB in case of new symptoms or
signs of rejection [4]. However, TBB has several limi-
tations; it may cause bleeding and complications and
may lead to sample errors. Therefore, a non-invasive
imaging tool to detect rejection after transplantation
is certainly needed.
Histopathological lesions, observed in acute rejection,
show perivascular and interstitial mononuclear cell infil-
trates in the pulmonary allograft [5], which are charac-
terised by high levels of activated cytotoxic T
lymphocytes overexpressing high-affinity interleukin-2
receptors (IL-2R), thus rendering T cells highly respon-
sive to interleukin-2 (IL-2) [1]. IL-2 binds specifically to
high-affinity IL-2R expressed on the cell membrane of
activated T lymphocytes [6]. When labelled with a suit-
able radionuclide, IL-2 could be used as a probe to visu-
alise lymphocyte infiltration by nuclear molecular
imaging. To date, clinical research with radiolabelled
IL-2 (e.g. 99mTc-HYNIC-IL-2 [7]) has been performed in
various inflammatory diseases in over 1000 patients (in-
flammatory bowel disease, atherosclerosis, thyroiditis,
diabetes type 1, etc.) [6, 8, 9].
In this proof-of-concept study, we investigated if acute
allograft rejection can be detected by 99mTc-HYNIC-IL-2
scintigraphy, including single-photon emission computed
tomography/computed tomography (SPECT/CT), in lung
transplant recipients shortly after transplantation.
Methods and materials
Thirteen lung transplant recipients were included in this
study. All recipients were > 18 years and provided writ-
ten informed consent. Maintenance immunosuppression
consisted of tacrolimus, mycophenolate mofetil, and
prednisolone. Patients were clinically assessed prior to
the scan to see if they had ongoing viral infections. The
study was approved by the local Medical Ethics Commit-
tee (trial number 2009/219).
99mTc-HYNIC-IL-2 scintigraphy was performed shortly
before the first routine bronchoscopy (TBB as reference
standard) after transplantation (median 1 day, maximum
15 days). This bronchoscopy was performed several
weeks after transplantation (median 36 days, minimum
19 days, maximum 126 days). 99mTc-HYNIC-IL-2 was
produced as previously described [7], and the preferred
injection dose was 185MBq (range of administered
dose 92–192MBq). Planar anteroposterior images of
the thorax and abdomen were acquired 60 min (range
55–67) after the administration of the radiopharma-
ceutical, followed by SPECT/CT of the thorax, SPECT
for quantification, and low-dose CT for anatomic
co-localization and attenuation correction. All images
were acquired on a SPECT/CT gamma camera system
(Siemens Symbia T, Siemens Medical Systems, Knox-
ville, TN, USA). The scans were analysed by two ex-
perienced nuclear medicine specialists (AG, RS) who
were blinded to all patient information except sex,
type of transplant (unilateral or bilateral), and time
between transplantation and scan. The reviewers
assessed the scans and scored the likelihood of acute re-
jection (rejection unlikely or rejection likely). If there was
a disagreement between the reviewers, the case was
reviewed together for consensus. The planar images were
scored according to a grading system: grade 0, no uptake;
grade 1, uptake lower than mediastinum; grade 2, uptake
equal to mediastinum; and grade 3, uptake higher than
mediastinum. Grades 2 and 3 were scores as rejection
likely, and grades 0 and 1 as rejection unlikely. For the
SPECT/CT images, the grading system was the same, but
the grading scores were given for each lobe. If at least one
lobe was scored with grade 2 or 3, this was regarded as re-
jection likely. Semiquantitative analysis on SPECT/CT im-
ages was performed by drawing the volume of interests
around the lungs and dividing the number of counts per
millilitre in the lung(s) by the counts per millilitre in refer-
ence tissues (aorta, bone marrow, and muscle) to calculate
the target-to-background ratio (T/B). TBBs were assessed
by an experienced pulmonary pathologist (WT). The
TBBs were graded according to the criteria of the Inter-
national Society for Heart and Lung Transplantation
(ISHLT) [10]. On histology, acute rejection was defined as
an ISHLT A score ≥ 1.
Correlation between IL-2 scintigraphy results and hist-
ology was assessed with Spearman’s rho. Additionally,
sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) with 95% confi-
dence intervals (95% CI) were calculated.
Results
In Table 1 the characteristics of the 13 patients are pre-
sented. None of the patients showed signs of viral infec-
tion. Ten patients underwent bilateral lung
transplantation and 3 unilateral transplantation. In 2 pa-
tients, no TBBs were available. In 1 patient, there was a
non-accessible stenosis of the airway anastomosis during
bronchoscopy. In the other patient, no assessable mater-
ial was found in the biopsy. Three patients showed acute
rejection in the TBB. In 2 of these patients, the scan was
scored (both on planar as on SPECT images) as rejection
likely. In the other patient, the scan was scored as rejec-
tion unlikely. In patients without rejection in the biop-
sies, no scans were scored as rejection likely. The
correlation between the rejection on biopsies and the
visual assessment of the scans was 0.77 (p = 0.006). The
calculated sensitivity was 67% (95% CI 13–100%), the spe-
cificity was 100%, the positive predictive value was 100%,
and the negative predictive value was 89% (68–100%). No
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correlation was found between the rejection on biopsies
and the T/B ratios on SPECT/CT (data not shown).
Discussion
In this proof-of-concept study, despite the low number
of patients, we show that 99mTc-HYNIC-IL-2 scintig-
raphy is able to detect acute rejection in lung transplant
recipients shortly after transplantation (Fig. 1). Maybe
even more important, in future, it may provide a tool to
avoid transbronchial biopsies when the imaging is nega-
tive or to improve the yield of these biopsies when posi-
tive. One of the benefits of imaging acute rejection with
radiolabelled IL-2 is its non-invasive nature. TBBs,
which are usually performed under general anaesthesia,
are invasive and may lead to complications [1]. Further-
more, imaging with radiolabelled IL-2 can assess the en-
tire lung, whereas TBBs are taken at random throughout
the lung. This may lead to sampling errors.
Table 1 Patient characteristics





ISHLT A ISHLT B ISHLT C ISHLT D Assessment of acute
rejection
1 46 Female Pulmonal hypertension Bilateral 0 0 0 0 Rejection unlikely Rejection unlikely
2 47 Female COPD Unilateral (L) 0 0 0 0 Rejection unlikely Rejection unlikely
3 30 Male Cystic fibrosis Bilateral – 1R 0 0 – Rejection unlikely
4 51 Male COPD Bilateral 2 0 1 0 Rejection Rejection likely
5 48 Female Pulmonal hypertension Bilateral 0 0 0 0 Rejection unlikely Rejection unlikely
6 52 Female COPD Bilateral 0 1R 0 0 Rejection unlikely Rejection unlikely
7 63 Male COPD Bilateral 0 0 0 0 Rejection unlikely Rejection unlikely
8 62 Male Fibrosis Bilateral – – – – – Rejection unlikely
9 53 Male COPD Bilateral 0 1R 0 0 Rejection unlikely Rejection unlikely
10 38 Male Cystic fibrosis Bilateral 0 0 0 0 Rejection unlikely Rejection unlikely
11 59 Female COPD Unilateral (R) 0 0 0 0 Rejection unlikely Rejection unlikely
12 47 Male Alpha-1-antitrypsine
deficiency
Bilateral 3 1R 0 0 Rejection Rejection likely
13 64 Female Bronchiolitis Unilateral (R) 1 0 0 0 Rejection Rejection unlikely
COPD chronic obstructive pulmonary disease, ISHLT The International Society for Heart and Lung Transplantation, IL-2 interleukin-2
Fig. 1 99mTc-HYNIC-IL-2 scintigraphy. Upper row images: anterior (left) and posterior (right) static view of a patient without rejection, showing
intense uptake in the liver and moderate uptake in the mediastinum/blood pool. Lower row images: anterior (left) and posterior (right) static
view of a patient with rejection, showing intense uptake in the liver, moderate uptake in mediastinum/blood pool, and increased uptake in the
basal and posterior parts of the lungs (uptake equal to mediastinum)
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The one patient with acute rejection in the TBB who
had a negative scan showed only minimal rejection in
the TBB (grade A1). On the other hand, the 2 patients
with both a positive scan and acute rejection in the TBB
showed mild to moderate acute rejection (grade 2 and
3). Therefore, the sensitivity of this SPECT technique
may be too low to detect minimal rejection.
Since T cells with increased IL-2R expression are also
upregulated in patients with viral infections [11], we ad-
vise to exclude patients with a possible viral infection
before performing radiolabelled IL-2 imaging, to in-
crease specificity. In our study, the patients were clinic-
ally assessed prior to the scan for viral infections and
showed no signs of viral infection.
In this study, we used 99mTc-HYNIC-IL-2, a SPECT
radiopharmaceutical. Recently, we developed a new IL-2
tracer labelled with fluorine-18 (18F), suitable for im-
aging with positron emission tomography/computed
tomography (PET/CT) [12]. The use of PET/CT imaging
improves image resolution and allows for the absolute
quantification of IL-2 uptake in lung regions, most likely
increasing sensitivity.
Our study suggests that non-invasive imaging with
radiolabelled IL-2 can be a promising new tool in the
detection and perhaps also the exclusion of acute rejec-
tion in patients after lung transplant. Further studies
with larger patient populations are needed to determine
the value of radiolabelled IL-2 imaging, preferably with
the PET tracer. Possible applications of IL-2 imaging
may be (1) in addition to TBB, to guide TBB to possible
sites of rejection, or (2) to possibly avoid TBB in case of
negative imaging.
Conclusion
In conclusion, in this proof-of-concept study, 99mTc-HY-
NIC-IL-2 scintigraphy proved to be a good technique to
detect grades 2 and 3 acute rejection in a small sample
population of patients after lung transplantation. Larger
studies are necessary to really show the added value of
this non-invasive specific imaging technique over TBB.
Alternatively, imaging with the PET tracer 18F-IL-2 may
be useful for this purpose.
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